结直肠癌奥沙利铂、5-Fu耐药的临床相关性研究(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 对结直肠癌根治术后接受奥沙利铂(LOHP)、5-Fu辅助化疗患者的耐药性进行评价。 方法 对在我院接受LOHP方案辅助化疗的150例患者的临床资料进行回顾性分析。包括两种化疗方案：LOHP联合持续灌注5氟尿嘧啶(5-Fu)和亚叶酸钙(CF)的两周方案(A组)、LOHP联合快速输注5-Fu和CF的3周方案。结果 A组治疗总有效率为43.9%，B组治疗总有效率为35.29%，两组比较有差异；两组均有一定的毒副反应，两组比较无差异。 结论 科学合理配伍使用奥沙利铂和5-Fu能有效拮抗辅助化疗的耐药性，延长结直肠癌患者寿命。
[关键词] 奥沙利铂；5-氟尿嘧啶；结直肠癌；耐药性
[中图分类号] R735.3 [文献标识码] A [文章编号] 1673-7210(2012)07(c)-0062-03
Study on the multidrug resistance of colorectal cancer between oxaliplatin and 5-Fu
OUYANG Manzhao CHEN Xiaowu ZHU Dajian JU Yongle WU Jinhao LI Yong
Department of Gastrointestinal Surgery, the First People's Hospital of Shunde District in Foshan City, Guangdong Province, Foshan 528000, China
[Abstract] Objective To analyze the drug resistance of colorectal patients which received adjuvant chemotherapy based on oxaliplatin and 5-Fu after operation. Methods Clinical data of 150 patients who had received adjuvant chemotherapy based on oxaliplatin and 5-Fu in our hospital were analyzed retrospect tively. There were two different chemotherapy regimens: Biwee-ekly oxaliplatin combined with continuous intravenous infused 5-Fu and leucovorin (LV) (FOLFOX4), triweekly oxaliplatin combined with bolus 5-Fu and LV (LOHP/Fu/LV). Results FOLFOX4 treatment group total effective rate was 43.9%, LOHP/Fu/LV group treatment efficiency was 35.29%, there were significant difference; the two group had a certain toxicity, no significant difference. Conclusion Scientific and reasonable use of compatibility of oxaliplatin and 5-Fu can effectively antagonize adjuvant chemotherapy drug resistance, prolong the life of patients with colorectal cancer.
[Key words] Oxaliplatin; 5-Fu; Colorectal cancer; Drug resistance
随着经济的发展，人们生活水平的提高以及饮食结构的改变，佛山市顺德区结直肠癌的发病率呈上升趋势，现已跃升至各种恶性肿瘤发病率的第四位，严重地危害着人们的健康。目前，结直肠癌的治疗手段包括手术、放疗、化疗以及生物治疗等，外科手术对于晚期结直肠癌的治疗效果不理想，化疗已成为治疗中晚期结直肠癌的主要手段之一 ......
您现在查看是摘要介绍页，详见PDF附件(2277kb)。